临床试验/IRCT20220211053992N20

IRCT20220211053992N20招募中Unknown

In vivo Bioequivalence study of Aspirin 80 mg tablet manufactured by MehrDarou Pharmaceutical Co. Compared to innovator Product

Tabriz University of Medical Sciences0 个研究点目标入组 24 人开始时间: 待定最近更新: 2024年1月22日

试验速览

阶段: Unknown
状态: 招募中
发起方: Tabriz University of Medical Sciences
入组人数: 24

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional

入排标准

年龄范围: 18 years 至 59 years（—）
性别: All

入选标准

•General Health (in terms of Liver, Heart and Kidney diseases)
•Age between 18 to 60 years

排除标准

•History of cardiovascular, liver, and kidney disease
•Alcohol and drug addiction
•History of drug allergy

研究者

发起方

Tabriz University of Medical Sciences

相似试验

In vivo Bioequivalence study of Aspirin tablet

IRCT20220211053992N6Tabriz University of Medical Sciences24

Aspirin tablets 81mg (ASPIRIN® 81mg) Kharazmi , In- Vivo Bioequivalence in Iranian healthy volunteers.

IRCT20200105046010N10Tabriz University of Medical Sciences24

Effectiveness of Aspirin 80, Aspirin 325, Enoxaparin and Rivoroxaban in Prevention of Coagulopathy after Total Knee Arthroplasty

IRCT20181128041784N1Hamedan University of Medical Sciences124

Comparison of the effect of Aspirin at doses of 80 and 160 mg on the prevention of preeclampsia in women with abnormal Doppler ultrasound of the uterine arteryPre-eclampsia

IRCT20210804052071N1Sabzevar University of Medical Sciences300

In-vivo Bioequivalence Study of ASA 80 mg EC Tablet of The Test Drug (Sajjad Darou, Iran)This study is performed on healthy volunteers and drug concentration in plasma is determined..

IRCT20200105046010N114Sajad darou shargh24